Related Experiment Video

Updated: Sep 29, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Anti-tumor effects of toxins targeted to the prostate specific membrane antigen

Giulio Fracasso1, Giuseppe Bellisola, Sara Cingarlini

  • 1Section of Immunology, Department of Pathology, University of Verona, Verona, Italy.

The Prostate
|September 5, 2002
PubMed
Abstract

Insights

New immunotoxins targeting prostate specific membrane antigen (PSMA) show promise for treating advanced prostate cancer. These antibody-drug conjugates effectively kill cancer cells while sparing healthy ones, offering a potential new therapy.

Area of Science:

  • Oncology
  • Immunotherapy
  • Molecular Biology

Background:

  • Advanced prostate cancer, specifically relapsing, metastatic, and androgen-independent forms, lacks effective treatments.
  • Immunotherapy utilizing immunotoxins (ITs) presents a potential novel therapeutic strategy for prostate cancer management.

Purpose of the Study:

  • To evaluate the efficacy of anti-prostate specific membrane antigen (anti-PSMA) immunotoxins in preclinical prostate cancer models.
  • To determine the cytotoxic effects of these immunotoxins on prostate cancer cells in vitro.

Main Methods:

  • Three anti-PSMA monoclonal antibodies (J591, PEQ226.5, PM2P079.1) were conjugated to ricin A-chain (RTA).
  • Cytotoxic effects were assessed using monolayer and 3-D cell cultures of LNCaP prostate carcinoma cells.

Main Results:

  • Anti-PSMA immunotoxins demonstrated potent activity against PSMA-positive cells, with IC50 values in the nanomolar range.
  • PSMA-negative cell lines exhibited significantly lower sensitivity (62- to 277-fold), indicating a therapeutic window.
  • One immunotoxin, J591-smpt-nRTA, achieved complete eradication of 3-D tumor micromasses at specific doses.

Conclusions:

  • Anti-PSMA immunotoxins show significant potential for eradicating prostate cancer cell aggregates in tissues and bone marrow.
  • These findings support further development of anti-PSMA immunotoxins as a targeted therapy for advanced prostate cancer.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System06:23

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.